Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 3/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.45 |
| ▸ | PRCP | P42785 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30182795 | 1.00 | DPP4 (0.47) | DPP4FAAHACEACE2PRCP | |
| SCHEMBL30182755 | 1.00 | DPP4 (0.47) | DPP4FAAHACEACE2PRCP | |
| SCHEMBL30182675 | 1.00 | DPP4 (0.47) | DPP4FAAHACEACE2PRCP | |
| SCHEMBL30182974 | 0.99 | DPP4 (0.48) | DPP4FAAHACEACE2OPRD1 | |
| SCHEMBL12696076 | 0.88 | ACE (0.56) | DPP4FAAHACEACE2PRCP | |
| SCHEMBL18112676 | 0.88 | ACE (0.56) | DPP4FAAHACEACE2PRCP | |
| SCHEMBL31324105 | 0.86 | DPP4 (0.45) | DPP4HTR1AHTR7 | |
| SCHEMBL29195203 | 0.86 | DPP4 (0.53) | DPP4HTR1AHTR7 | |
| SCHEMBL31324122 | 0.85 | DPP4 (0.46) | DPP4HTR1AHTR7 | |
| SCHEMBL16229682 | 0.85 | DPP4 (0.54) | DPP4HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479856-B2 | Pharmaceutical compounds for the treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| CN-113795249-B | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20230085372-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479856-B2 | Pharmaceutical compounds for the treatment of complement mediated disorders | C5, CFH, C1QBP | DPP4 1272/4885FAAH 2190/4885ACE 279/4885 |
| US-20230085372-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, CFH, C1QBP | DPP4 1272/4885FAAH 2190/4885ACE 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.